• U.S. Burden of Skin and Subcutaneous Diseases Increasing

    Healthday News Conditions, HealthDay News Physician's Briefing June 25, 2020
  • Can dermatology employers require employees to receive the COVID-19 vaccine?

    American Academy of Dermatology AAD, Conditions, Coronavirus, COVID-19 January 28, 2021
  • THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

    American Academy of Dermatology AAD, Atopic Dermatitis, Conditions, Dermatology January 26, 2021
  • Expression of retinoid receptors in hand eczema.

    ClinOwl Atopic Dermatitis, ClinOwl, Conditions, Eczema October 1, 2020
  • S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

    Healthday News Atopic Dermatitis, Conditions, Eczema July 28, 2020
  • Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

    ClinOwl ClinOwl, Conditions, COVID-19, Psoriasis July 26, 2020

DermConnect® is an official licensee of the American Academy of Dermatology.

DermConnect®
Navigation
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
Home Posts Dermatology

Category Archive

  • Dermatology / November 30, 2020

    Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial.

    View Post
  • Dermatology / March 30, 2021

    Change in lentigo maligna score assessed by in vivo reflectance confocal microscopy after one month of imiquimod treatment for lentigo maligna management.

    View Post
  • Dermatology / June 20, 2021

    Outcomes of Pregnancy and Childbirth in Women with Hidradenitis Suppurativa.

    View Post
  • Dermatology / February 7, 2021

    Simvastatin in vitiligo: an update with recent review of the literature.

    View Post
  • Dermatology / March 29, 2021

    The Association between Citrus Consumption and Melanoma Risk in the UK Biobank.

    View Post

Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.

In Dermatology
by ClinOwl
May 5, 2021

Nonsteroidal anti-inflammatory drugs (NSAIDs), probably the most consumed medicines, are the main triggers of drug hypersensitivity, being NSAID-induced acute urticaria/angioedema (NIUA) the most frequent phenotype. NSAID-hypersensitivity is bred by cyclooxygenase …

Chronic lymphocytic leukemia and the skin: implications for the dermatologist.

In Dermatology
by ClinOwl
May 4, 2021

B-cell chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United States, and its diagnosis can have many dermatologic implications. For one, the cutaneous manifestations of CLL include …

Dermatologic Support for Oncology: Quantifying the consultative services received by hospitalized oncology patients.

In Dermatology
by ClinOwl
May 4, 2021

Dermatology was the fifth most utilized consultative service by Oncology when compared to the 101 other inpatient consultative services. Patients receiving dermatology consults had longer lengths of stay. Previous work …

Effects of ısotretinoin on the growth rate and thickness of the nail plate.

In Dermatology
by ClinOwl
May 4, 2021

Isotretinoin has various effects on nails. However, the mechanism of how isotretinoin affects the nail plate is unknown. We aimed to investigate the effects of isotretinoin on morphology, growth rate, …

Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.

In Dermatology
by ClinOwl
May 3, 2021

The early diagnosis of cutaneous T-cell lymphomas (CTCL) may be challenging and based on a combination of clinical, biological, histological, and molecular criteria (1). View the full article @ The …

Proof-of-concept for clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase 2 BELIEVE study.

In Dermatology
by ClinOwl
May 3, 2021

Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in pemphigus pathophysiology, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK …

Reporting of randomized controlled trial abstracts in dermatology journals according to CONSORT guidelines.

In Dermatology
by ClinOwl
May 3, 2021

Clinicians often only read the abstracts of studies1,2 so accurate and complete reporting of randomized clinical trial (RCT) abstract is essential. The Consolidated Standards of Reporting Trials extension for Abstracts …

Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management.

In Dermatology
by ClinOwl
May 3, 2021

Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic …

Treatment of Pediatric Alopecia Areata: A Systematic Review.

In Dermatology
by ClinOwl
May 2, 2021

Alopecia areata (AA) is an autoimmune, non-scarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is …

Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire.

In Dermatology
by ClinOwl
May 2, 2021

The symptoms and appearance of vascular malformations can severely harm a patient’s quality of life. The aim of treatment of vascular malformations generally is to improve condition-specific symptoms and/or appearance. …

  • Page 10 of 57
  • ←
  • 1
  • ...
  • 9
  • 10
  • 11
  • ...
  • 57
  • →

TRENDING

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease
  • Lymph Node Dissection Declining in SLN-Positive Melanoma
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

LATEST ARTICLES

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus March 16, 2022
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites March 11, 2022
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease March 11, 2022
  • Lymph Node Dissection Declining in SLN-Positive Melanoma March 9, 2022
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down March 9, 2022

Quick Links

  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

SCHEDULE

May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
« Mar    

All content indicated on this website as authored by "AAD" is owned by and licensed with the permission of the American Academy of Dermatology (“AAD”) for personal educational use.

The content may not be distributed in whole or in part to any third parties without express written permission from AAD,
nor may viewers of this site translate, edit, modify or otherwise create derivative works from the content.

The licensing of the content by AAD does not constitute or imply any endorsement of any company and/or any of its goods, services or written work product.

 

  • Home
  • Atopic Dermatitis
  • Psoriasis
  • Skin Cancer